Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 25, 2023
Data Byte
Aggressive cuts part of Novartis’ focus on higher-potential pipeline
The pharma’s latest quarterly update revealed a pruning of 10% of its pipeline, including several early-stage cancer programs
BioCentury | Feb 23, 2023
Deals
Redx adds U.S. office while Jounce shareholders eye CVR’s upside in merger
Combined company will prioritize U.K. company’s ROCK2 program as deal adds to Redx’s balance sheet
BioCentury | Aug 6, 2020
Product Development
Aug. 5 Quick Takes: Strong quarterly sales of Horizon’s Tepezza, Global Blood’s Oxbryta; plus a setback for DBV and news from Point, Karuna, Evotec-Secarna, Red
BioCentury | Jul 11, 2019
Targets & Mechanisms
The tumor stroma rises as the newest source of immuno-oncology targets
Why companies are turning to the tumor stroma to overcome resistance to checkpoint inhibitors
BioCentury | May 12, 2016
Distillery Therapeutics
Therapeutics: β-catenin (CTNNB1); ubiquitin specific peptidase 6 (USP6)
Items per page:
1 - 9 of 9